KRAS and intrahepatic cholangiocarcinoma: Gain-of-function mutations in KRAS and NRAS have been previously described in ICC (8) and through our IntOGen analysis, we similarly identified recurrent mutations in both of these genes (KRAS 18.05% and NRAS 2.88%, Supplementary Table S4).